Home > Insider Trading > Filing (0001209191-20-061734)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1496323	Igm Biosciences Inc.	IGMS	Pharmaceutical Preparations (2834)	770349194

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1787681	Shinyu Daniel Chen	C/O Igm Biosciences, Inc. 325 E. Middlefield Road Mountain View CA 94043	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-12-01	950	$1.39	117,423	No	4	M	Direct
Common Stock	Disposition	2020-12-01	342	$64.22	117,081	No	4	F	Direct
Common Stock	Disposition	2020-12-02	608	$63.15	116,473	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	F	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2020-12-01	950	$0.00	950	$1.39

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
353,490		2028-12-30	No	4	M	Direct

Footnotes

The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
Represents shares withheld by the Issuer to pay the exercise price and taxes pursuant to the "net exercise" of 950 option shares.
This transaction was executed in multiple trades at prices ranging from $63.15 to $63.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
The option, originally for 361,090 shares, of which 7,600 shares have been exercised, vested as to 1/4 of the shares on August 1, 2019, and an additional 1/48 of the shares subject to the option shall vest monthly thereafter, subject to the Reporting Person remaining a service provider through each such date.